NOD2, IL23R and ATG16L1 polymorphisms in Lithuanian patients with inflammatory bowel disease

Table 3 Association statistics for the NOD2, ATG16L1 and IL23R variants in the Lithuanian IBD population

Gene marker	Minor allele	Controls (n = 186)			CD (n = 56)				UC (n = 123)
		GT (11/12/22)	MAF	PHWE	GT (11/12/22)	MAF	PCCA	OR (95% CI)	GT (11/12/22)	MAF	PCCA	OR (95% CI)
NOD2
rs2066844	T	0/9/171	0.025	> 0.99	0/2/54	0.018	> 0.99	0.71 (0.15-3.33)	0/10/113	0.041	0.278	1.65 (0.66-4.13)
rs2066845	C	1/7/169	0.025	0.099	0/3/53	0.027	> 0.99	1.06 (0.28-3.97)	0/1/121	0.004	0.055	0.16 (0.02-1.25)
rs2066847	insC	2/13/166	0.047	0.048	4/16/36	0.214	3.687 × 10-8a	5.54 (2.85-10.75)	1/8/114	0.041	0.711	0.86 (0.39-1.91)
ATG16L1
rs2241880	G	44/89/53	0.476	0.560	16/28/11	0.546	0.199	1.32 (0.86-2.03)	33/61/25	0.534	0.164	1.26 (0.91-1.75)
IL23R
rs11209026	A	3/16/167	0.059	0.017	0/4/52	0.036	0.335	0.59 (0.20-1.75)	0/11/109	0.045	0.477	0.76 (0.36-1.61)

Minor allele frequencies (MAF), genotype counts (GT; 11 = homozygous for minor allele; 12 = heterozygous for common allele; 22 = homozygote for common allele), allelic test P values (^aP_CCA < 0.05), and odds ratios (OR, shown for the minor allele) with 95% confidence intervals (CI) are depicted for both the CD and UC case-control population.